Label Changes for:

Invanz (ertapenem) injection

December 2009

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2009

ADVERSE REACTIONS

Postmarketing Experience
  • includes altered mental status (including aggression, delirium), dyskinesia, myoclonus, and tremor
Hide
(web1)